

# World Journal of *Obstetrics and Gynecology*

*World J Obstet Gynecol* 2012 August 10; 1(2): 3-16





## Editorial Board

2012-2016

The World Journal of Obstetrics and Gynecology Editorial Board consists of 100 members, representing a team of worldwide experts in obstetrics and gynecology. They are from 33 countries, including Australia (3), Austria (1), Belgium (3), Brazil (3), Canada (2), Chile (1), China (5), Egypt (2), Finland (1), France (2), Germany (1), Greece (4), India (4), Iran (2), Israel (3), Italy (6), Japan (2), Jordan (2), Malawi (1), Mexico (1), Netherlands (2), Nigeria (1), Norway (1), Saudi Arabia (2), Serbia (1), South Korea (2), Spain (2), Sweden (1), Thailand (1), Turkey (8), United Kingdom (7), United States (22), and Venezuela (1).

### EDITOR-IN-CHIEF

Bo Jacobsson, *Gothenburg*

### GUEST EDITORIAL BOARD MEMBERS

Wing P Chan, *Taipei*

Chie-Pein Chen, *Taipei*

Shi-Yann Cheng, *Beigang Town*

### MEMBERS OF THE EDITORIAL BOARD



#### Australia

Ashwini Chand, *Melbourne*

Steven D Fleming, *Brisbane*

Marjan Khajehei, *Como*



#### Austria

Susanne Huber, *Vienna*



#### Belgium

Marc FD Baay, *Antwerp*

Christophe Blockeel, *Brussels*

Yves Jacquemyn, *Edegem*



#### Brazil

Carlos KB Ferrari, *Barra do Garças*

Wellington P Martins, *Ribeirão Preto*

Maria Inês Rosa, *Criciúma*



#### Canada

Emmanuel Bujold, *Québec*

Paul James Hoskins, *Vancouver*



#### Chile

Patricio E Donoso, *Santiago*



#### China

Cherng-Jye Jeng, *Nanjing*

Jian-Xin Li, *Nanjing*



#### Egypt

Hesham E Abdel-Hady, *Mansoura*

Ahmed S El Hefnawy, *Mansoura*



#### Finland

Johan O Fellman, *Helsinki*



#### France

Cherif Y Akladios, *Strasbourg*

Souhail Alouini, *Orleans*



#### Germany

Safaa H Al-Hasani, *Luebeck*



#### Greece

Byron Asimakopoulos, *Alexandroupolis*

Anastasios Athanasopoulos, *Patra*

Christos R Iavazzo, *Athens*

Ioannis E Messinis, *Larissa*



#### India

Chinmoy K Bose, *Kolkata*

Ankit Jain, *Puducherry*

Pralhad Kushtagi, *Mangalore*

Niraj N Mahajan, *Mumbai*



#### Iran

Hossein Fallahzadeh, *Yazd*

Abbas A Ghaderi, *Shiraz*



#### Israel

Zeev Blumenfeld, *Haifa*

Sorina Grisaru-Granovsky, *Jerusalem*

Marwan Odeh, *Nahariya*



#### Italy

Sandrine ML Chamayou, *Sant'Agata Li Battiati*

Federico Coccolini, *Bergamo*

Erich Cosmi, *Padua*

Vassilios Fanos, *Cagliari*

Roberta Granese, *Messina*

Anna Maria Marconi, *Milano*



#### Japan

Madoka Furuhashi, *Nagoya*

Takeshi Maruo, *Kobe*

**Jordan**

Moamar I Al-Jefout, *Mutah*  
Zouhair O Amarin, *Irbid*

**Malawi**

Fanuel Lampiao, *Blantyre*

**Mexico**

Alfonso Dueñas-González, *Mexico*

**Netherlands**

Marieke J Claas, *Utrecht*  
Wendy Koster, *Utrecht*

**Nigeria**

Chibuike O Chigbu, *Enugu*

**Norway**

Andrej M Grjibovski, *Oslo*

**Saudi Arabia**

Ismail Al-Badawi, *Riyadh*  
Mamdoh AA Eskandar, *Abha*

**Serbia**

Miroslava G Gojnic Dugalic, *Belgrade*

**South Korea**

Kwang-Hyun Baek, *Seongnam*  
Min Hyung Jung, *Seoul*

**Spain**

J de la Torre Fernandez de Vega, *Tenerife*  
Javier Fernandez de Vega, *Tenerife*

**Thailand**

Pisake NA Lumbiganon, *Khon Kaen*

**Turkey**

Metin Akbulut, *Denizli*  
Cem Baykal, *İstanbul*  
Husnu Celik, *Elazig*  
Cem Dane, *İstanbul*  
Polat Dursun, *Ankara*  
Erdirin İlter, *İstanbul*  
Mehmet Kefeli, *Samsun*  
Kamile Kukulu, *Antalya*

**United Kingdom**

Suha Deen, *Nottingham*

Stergios K Doumouchtsis, *London*  
Mona A El-Bahrawy, *London*  
Alaa A El-Ghobashy, *Wolverhampton*  
Ayman AA Ewies, *Birmingham*  
Myra S Hunter, *London*  
Paul D Losty, *Liverpool*

**United States**

Mukhtar H Aliyu, *Nashville*  
Priya R Bhosale, *Houston*  
Donald P Braun, *Zion*  
Chunxia Cao, *Gainesville*  
Wally A Carlo, *Birmingham*  
Linda R Chambliss, *Phoenix*  
Teresa P Diaz-Montes, *Baltimore*  
Steven M Donn, *Ann Arbor*  
Omar F Duenas, *New York*  
Marilyn B Escobedo, *Oklahoma*  
Robert Freedman, *Detroit*  
Sergio G Golombek, *Valhall*  
Michael P Goodman, *Davis*  
Diane M Harper, *Kansas*  
Matthew H Ho, *Los Angeles*  
Patricia B Hoyer, *Tucson*  
William W Hurd, *Cleveland*  
Gabor B Huszar, *New Haven*  
Amer K Karam, *Los Angeles*  
Justin P Lavin Jr, *Akron*  
Zaher Merhi, *Bronx*  
Wenxin Zheng, *Tucson*

**Venezuela**

María E Aponte-Rueda, *Caracas*



## Contents

Bimonthly Volume 1 Number 2 August 10, 2012

### MINIREVIEWS

3

Survey of the management of borderline ovarian tumors in the United Kingdom

*Winser A, Ledermann JA, Osborne R, Gabra H, El-Bahrawy MA*

### OBSERVATION

14

Sexuality after childbirth: Gaps and needs

*Khajehei M*



## Contents

*World Journal of Obstetrics and Gynecology*  
Volume 1 Number 2 August 10, 2012

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Obstetrics and Gynecology*

**APPENDIX** I Meetings  
I-V Instructions to authors

**ABOUT COVER** *World Journal of Obstetrics and Gynecology* Editorial Board, Mona A El-Bahrawy, MBBCh, PhD, FRCPath, Department of Histopathology, Imperial College London, Hammersmith Hospital, DuCane Road, London W12 0HS, United Kingdom

**AIM AND SCOPE** *World Journal of Obstetrics and Gynecology* (*World J Obstet Gynecol*, *WJOG*, online ISSN 2218-6220, DOI: 10.5317) is a bimonthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 100 experts in obstetrics and gynecology from 33 countries.

The aim of *WJOG* is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of obstetrics and gynecology. *WJOG* covers pregnancy complications, obstetric surgical procedures, diagnostic imaging, endoscopy, reproductive endocrinology, tumors, pelvic diseases, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine, epidemiology and nursing. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to obstetrics and gynecology, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

**FLYLEAF** I-II Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Jin-Lei Wang  
Responsible Electronic Editor: Xiao-Mei Zheng  
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Xiu-Xia Song  
Proofing Editorial Office Director: Jin-Lei Wang

**NAME OF JOURNAL**  
*World Journal of Obstetrics and Gynecology*

**ISSN**  
ISSN 2218-6220 (online)

**LAUNCH DATE**  
June 10, 2012

**FREQUENCY**  
Bimonthly

**EDITING**  
Editorial Board of *World Journal of Obstetrics and Gynecology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: wjog@wjgnet.com  
http://www.wjgnet.com

**EDITOR-IN-CHIEF**  
Bo Jacobsson, MD, PhD, Associate Professor, De-

partment Obstetrics and Gynecology, Sahlgrenska University Hospital/Ostra, SE-416 85 Gothenburg, Sweden

**EDITORIAL OFFICE**  
Jian-Xia Cheng, Director  
Jin-Lei Wang, Vice Director  
*World Journal of Obstetrics and Gynecology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: wjog@wjgnet.com  
http://www.wjgnet.com

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai, Hong Kong, China  
Fax: +852-31158812  
Telephone: +852-58042046  
E-mail: bpg@baishideng.com  
http://www.wjgnet.com

**PUBLICATION DATE**  
August 10, 2012

**COPYRIGHT**  
© 2012 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2218-6220/g\\_info\\_20100722175812.htm](http://www.wjgnet.com/2218-6220/g_info_20100722175812.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esp/>

## Survey of the management of borderline ovarian tumors in the United Kingdom

Amy Winsor, Jonathan A Ledermann, Richard Osborne, Hani Gabra, Mona A El-Bahrawy

Amy Winsor, Clinical Trials Unit, The Royal Marsden Hospital, London SW3 6JJ, United Kingdom

Jonathan A Ledermann, UCL Hospitals Biomedical Research Centre, UCL Cancer Institute, London WC1E 6BT, United Kingdom

Richard Osborne, Dorset Cancer Centre, Poole Hospital, Dorset BH15 2JB, United Kingdom

Hani Gabra, Department of Oncology, Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom

Mona A El-Bahrawy, Department of Histopathology, Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom

**Author contributions:** Winsor A arranged the electronic development and distribution of the survey; Ledermann JA, Osborne R and Gabra H planned the survey questions; Osborne R revised the manuscript; El-Bahrawy MA designed and developed the survey, analyzed the responses and wrote the manuscript.

**Supported by** The NIHR Biomedical Research Centre

**Correspondence to:** Dr. Mona A El-Bahrawy, MBBCh, PhD, FRCPath, Department of Histopathology, Imperial College London, Hammersmith Hospital, DuCane Road, London W12 0NN, United Kingdom. [m.elbahrawy@imperial.ac.uk](mailto:m.elbahrawy@imperial.ac.uk)

Telephone: +44-20-83833442 Fax: +44-20-83838141

Received: May 9, 2012 Revised: June 24, 2012

Accepted: July 30, 2012

Published online: August 10, 2012

the management of borderline ovarian tumors in cancer centres representing different regions in the United Kingdom. In this article we review the literature for the current concepts in diagnosis, treatment and follow up of BOTs and we report the results of the survey of current practice in the United Kingdom. On that basis we provide recommendations for the management of patients with BOTs.

© 2012 Baishideng. All rights reserved.

**Key words:** Borderline; Ovarian; Tumors; Survey; Management

**Peer reviewer:** Sherri L Stewart, PhD, Team Lead, Division of Cancer Prevention and Control, Cancer Prevention and Control, Atlanta, GA 30341, United States

Winsor A, Ledermann JA, Osborne R, Gabra H, El-Bahrawy MA. Survey of the management of borderline ovarian tumors in the United Kingdom. *World J Obstet Gynecol* 2012; 1(2): 3-13 Available from: URL: <http://www.wjgnet.com/2218-6220/full/v1/i2/3.htm> DOI: <http://dx.doi.org/10.5317/wjog.v1.i2.3>

### Abstract

Borderline ovarian tumors (BOTs) represent approximately 10% of ovarian neoplasms and are a heterogeneous group of tumors with variable biological behaviour. The majority present with disease confined to the ovary and have an excellent prognosis after surgical removal. A small proportion subsequently has recurrent disease or progression to invasive cancer. Tumor recurrence can occur up to 20 years after surgical resection. There are no robust clinical, histological or molecular markers that distinguish high risk cases and no satisfactory treatment for patients with progressive disease. This results in great variability in management in different centres. We conducted a national survey on

### INTRODUCTION

Borderline ovarian tumors (BOTs) account for 10% of all ovarian neoplasms. Six hundred cases occur annually in the United Kingdom, mostly affecting women of reproductive age<sup>[1]</sup>. BOTs are a heterogeneous group of tumors with variable biological behaviour. The majority (85%) present with disease confined to the ovary and have an excellent prognosis after surgical removal. A small proportion subsequently have recurrent disease or progression to invasive cancer<sup>[1-5]</sup>.

As tumor recurrence tends to occur late, up to 20 years from original resection, many authors advocate long-term follow-up<sup>[6,7]</sup>. There are many controversies regarding the significance of different histological features that can be

seen in these tumors, and also regarding the best management and follow up strategies. Also there are no robust clinical, histological or molecular markers that distinguish high risk cases. Also, to date there is no satisfactory treatment for patients with progressive disease<sup>[8-12]</sup>.

There is no national protocol for the management of BOTs, yet the nature and extent of variability or uniformity of management between different centres of the UK is not documented. This has prompted us to carry out a structured survey addressing the current clinical management of BOTs to gain information that will help in the development of proposals for standardised management and prospective trials and to identify the demand for further education and research activities.

## QUESTIONNAIRE

A questionnaire was developed in a multistep process. Relevant topics and a list of questions were formulated by an expert group including gynaecological oncologists and pathologists. All possible answers and combinations were provided in a multiple-choice manner, with the additional option of free text in some parts. The drafted survey was finally reviewed and ratified by the steering committee of the Ovarian subgroup of the National Cancer Research Network (NCRN). The survey was approved and sponsored by the ovarian subgroup of the NCRN and the Scottish Gynaecological Clinical Trials Group.

The survey was sent to lead gynaecology clinicians in the 35 cancer networks *via* e-mail and the responses were received by e-mail or by post. The survey was launched in March 2010 and concluded in March 2011. All analyses were worked out in a primarily descriptive manner.

We received responses from representative hospitals in 16/35 (46%) cancer networks including East Midlands, Yorkshire, South West London, North London, Mount Vernon, Northern Ireland, West London, Dorset, Kent, Sussex, Greater Midland, Merseyside and Cheshire, North Wales, Anglia, Pan Birmingham, Leicester, Northampton, Rutland and West Scotland.

### **Incidence of BOTs**

To address the incidence of BOTs in different network hospitals, we asked the question “How many cases of BOTs are seen annually in your network?”: Fifteen centres answered this question. Seven network hospitals (47%) treat 11-15 cases per year, 1/15 (6%) treat 16-20 and 7/15 (47%) treat more than 20 cases a year.

To address the stage of tumors at presentation, we asked the question “In terms of stage, what is the breakdown of BOTs seen annually in your network?”: Compiling the data from 15 network hospitals it was found that the vast majority of tumors presented at stage I, followed by stages II and III. The incidence range in different centres was for stage I: 80%-97%, stage II: 1%-20% and stage III: 5%-30%.

To address the frequency of the different types of BOTs, we asked the question “In terms of histological type, what is the breakdown of BOTs seen annually in your network?”: Compiling the data from 15 network hospitals the incidence of serous tumors ranged between 25%-80% and mucinous tumors ranged from 20%-75%. In most centres serous tumors were the commoner type and only few centres reported a higher incidence of mucinous tumors. Few centres reported encountering other types ranging from 1%-10%.

### **Multidisciplinary team discussion**

To explore whether all BOTs were discussed in the multidisciplinary team meeting, we asked the question “Are all BOT cases discussed at the central cancer centre gynaecologic oncology multidisciplinary team meeting?”: All but one centre (94%) confirmed referral of all cases for multidisciplinary team (MDT) discussion. In the one centre cases are only referred for MDT discussion if there are implants, microinvasion, intramucosal carcinoma, the patient is considered for chemotherapy, has ascites and all advanced stage cases.

### **Surgical management, to address the surgical management, we asked the following questions**

“What percentage of patients diagnosed with BOTs undergo a formal cancer operation? (i.e., TAH and BSO, omentectomy, washings): Fourteen centres replied to this question. The number of patients who undergo a formal cancer operation in different centres varied, being 30% (1/14 centres), 50% (3/14 centres), 60% (1/14 centres), 70% (3/14 centres), 80% (3/14), 90% (2/14 centres) and 99% (1/14 centres).

To explore whether this was influenced by patients' desire to preserve fertility, we asked the question “Do all patients diagnosed with BOTs have full surgical staging if the patient does not consider fertility preservation?”: Sixteen centres answered this question. In 8/16 (50%) centres all patients who do not wish to preserve fertility undergo full surgical staging, whereas in 8/16 (50%) centres not all patients do.

To find if the type of surgery is decided by the histological type or special features in the tumor, we asked the question “Is the decision influenced by histological type or histological features?”: Fourteen centres answered this question. In 4/14 (29%) centres the decision is influenced by tumor type and histological features, but not in 10/14 (71%).

“If yes, does this include lymphadenectomy?”: Eleven centres replied to this question. All but two centres (81%) do not do lymphadenectomy.

“Do you recommend completion surgery to all patients after completing their family?”: Fourteen centres replied to this question. In 5/14 (36%) centres completion

**Table 1 Different follow up protocols in the United Kingdom**

Follow up (82% of centres)
Follow up for 5 yr at 3 and 9 mo, then 3 monthly for 2 yr then 6 monthly for 3 yr
Follow up for 5 yr, 3 monthly for the first 2 yr then 6 monthly onwards
Follow up for 5 yr at 6-12 mo, depending on the pathology
Follow up for 5 yr; 3 monthly for the first year, 4 monthly for the second year, 6 monthly for third year, and then annually for the fourth and fifth years
Follow up for 5 yr; every 6 months for 2 yr, then once a year for further 3 yr
Follow up for 3 yr, six monthly
All stage I patients are discharged. Patients with stages II and III disease are followed up: 3 monthly for 1 yr, 4 monthly for year 2 and 6 monthly for a third year
Stage I A fully staged are discharged, and all other patients have annual follow up for 10 yr
Stage I A completely staged are discharged and all other patients are followed up 6 monthly for 2 yr then annually up to 10 yr then every other year up to 20 yr
Stage I A fully staged are discharged, and all other patients are followed up monthly for 2 yr, then once in the third year and then discharged
Follow up is patient initiated. However, patients who retain their ovary are followed up by ultrasound every 6 mo
Follow up for patients who had fertility sparing surgery 6 monthly for life
Patients with Stage I disease have only one follow up visit. Patients with stage III are followed for several years
No follow up (18% of centres)

surgery is not recommended. In 2/14 (14%) this option is offered and discussed with the patient, but not recommended, while 7/14 (50%) recommended completion surgery.

**To study that in more detail, we asked “When a BOT has been identified and full staging surgery has not been performed, what are your local policies with regards to future management?”:** Fifteen centres answered this question. Four centres (27%) offer all options including no further surgery, full surgical staging and full surgical staging after completion of family; recommendation is individualised to patients. In 6/15 (40%) centres no further surgery is recommended. In 2/15 (13%) they perform full surgical staging and in 3/15 (20%) centres they perform full surgical staging after completion of family.

**Follow up, to explore follow up protocols for patients in different centres, we asked the following questions**

**“Are patients offered regular follow-up appointments at your institution?”:** All centres replied to this question and 14/17 (82%) confirmed having a follow up protocol, while 3/17 (18%) centres do not follow up patients with BOTs.

**“If patients are offered regular follow up appointments, what is the frequency of these visits and the duration of the follow up?”:** Each of the fourteen centres that responded to this question had a different follow up protocol. These were: (1) Follow up for 5 years at 3 and 9 mo, then 3 monthly for 2 years then 6 monthly for 3 years; (2) Follow up for 5 years, 3 monthly for the first 2 years then 6 monthly onwards; (3) Follow up for 5 years at 6-12 mo, depending on the pathology; (4) Follow up for 5 years; 3 monthly for the first year, 4 monthly for the second year, 6 monthly for third year, and then annually for the fourth and fifth years; (5) Follow up for 5 years; every 6 mo for 2 years, then once a year for further 3 years; (6) Follow up for 3 years, six monthly; (7) All stage I patients are discharged. Patients

with stages II and III disease are followed up: 3 monthly for 1 year, 4 monthly for year 2 and 6 monthly for a third year; (8) Stage I A fully staged are discharged, and all other patients have annual follow up for 10 years; (9) Stage I A completely staged are discharged and all other patients are followed up 6 monthly for 2 years then annually up to 10 years then every other year up to 20 years; (10) Stage I A fully staged are discharged, and all other patients are followed up monthly for 2 years, then once in the third year and then discharged; (11) Follow up is patient initiated. However, patients who retain their ovary are followed up by ultrasound every 6 mo; (12) Follow up for patients who had fertility sparing surgery 6 monthly for life; (13) Patients with Stage I disease have only one follow up visit. Patients with stage III are followed for several years; and (14) Varies around the region, no details given. Table 1 summarises the follow up protocols in different centres of the United Kingdom.

**“What tests and/or examinations are undertaken at these follow up appointments?”:** Fifteen centres answered this question. In 4/15 (26%) centres patients undergo physical examination and serum CA 125; in 3/15 (20%) patients undergo physical examination and transvaginal ultrasound, in 2/15 (13%) patients undergo physical examination and if the patient has a retained ovary then transvaginal ultrasound is done as well. In 1/15 (7%) patients undergo transvaginal ultrasound only, in 1/15 (7%) CA 125, in 2/15 (13%) physical examination, CA 125 and transvaginal ultrasound and in 1/15 (7%) physical examination, CA 125 and if the patient had fertility sparing surgery then transvaginal ultrasound as well and in 1/15 (7%) CA 125 and computed tomography scan.

**“Does the follow up protocol vary according to the patient’s age?”:** Thirteen centres answered this question. In 9/13 centres (69%) age had no effect and in 4/13 (31%) the protocol varied with age.

**“Does the follow up protocol vary if the patient had**



**Table 2 Management of relapsed disease in different United Kingdom centres**

Management	Percentage of centres (%)
Surgery only	53
Surgery followed by chemotherapy	13
Surgery followed by chemotherapy only if there is invasive disease	13
Chemotherapy followed by surgery	7
Chemotherapy only	7
Variable depending on MDT decision	7

MDT: Multidisciplinary team.

**fertility sparing surgery?”:** Fourteen centres answered this question. In 12/14 (86%) centres the follow up protocol for patients who had fertility sparing surgery was different from patients who had full staging, but in two centre all patients were followed up according to one protocol.

**“If a patient fails to attend their follow up clinic appointment, what is your institution’s policy?”:** Twelve centres answered this question. In 8/12 (67%) centres patients are sent a reminder letter with a new appointment. Three centres (25%) send a reminder letter to the patient with new appointment and letter to the GP for persistent non attendees. In one centre (8%), follow up was patient induced.

#### **Management of relapsed disease, to address management of relapsed disease, we asked the following questions**

**“How do you manage relapsed disease?”:** Fifteen centres answered this question. In 8/15 (53%) relapsed disease is treated by surgery only. In 2/15 (13%) centres they use surgery followed by chemotherapy, in 1/15 (7%) usually chemotherapy, in 1/15 (7%) chemotherapy or surgery followed by chemotherapy, 1/15 (7%) variable depending on MDT decision, 2/15 (13%) surgery followed by chemotherapy if there is invasive disease. Table 2 summarises the different management protocols used in the United Kingdom for relapsed disease.

**When using chemotherapy for treating tumor relapse or progressive disease what is your current regimen of choice in:** (1) In the adjuvant setting: Thirteen centres answered this question. In 4/13 centres (31%) chemotherapy is used, in 6/13 centres (46%) no chemotherapy is used, in 3/13 (23%) no chemotherapy is used unless invasive disease is present. In centres that use chemotherapy 3 centres use taxol/carboplatin, in 2 carboplatin  $\pm$  taxol, in 1 platinum based treatment only and in 1 centre the choice of chemotherapy was not given; and (2) First line treatment of advanced (stage III or recurrent) disease: Twelve centres answered this question. In one centre no chemotherapy is used, in 5/12 carboplatin and taxol are used; in 2/12 carboplatin alone and in 3/12 carboplatin  $\pm$  taxol are used. One centre uses carboplatin or enrolls the

**Table 3 Use of chemotherapy in treatment of borderline ovarian tumors in United Kingdom centres**

Use of chemotherapy	Percentage of centres (%)
In the adjuvant setting	
No chemotherapy used	46
Chemotherapy used only if there is invasive disease	23
Chemotherapy used	31
First line treatment of advanced (stage III or recurrent) disease	
No chemotherapy used	8.3
Chemotherapy used	91.6

Chemotherapy used is carboplatin  $\pm$  paclitaxel.

patient in a phase I study. One centre does not use chemotherapy. Table 3 summarises the use of chemotherapy in management of BOTs in the United Kingdom.

#### **Pathological assessment**

**“What sampling protocol is used for examining BOTs at your institution?”:** Twelve centres answered this question. Only three centres reported that pathologists sample 1 block per centimetre of tumor largest dimension and in one centre more than 1 block per centimetre is sampled. In 7/12 (58%) centres sampling varies according to macroscopic appearance.

**“Does this protocol vary according to histological sub type?”:** Twelve centres answered this question. In 8/12 (67%) centres the protocol did not vary with the histological type of tumor and in 4/12 (33%) it did.

**“Do your histopathologists routinely provide tumor staging in the histology report for BOTs?”:** Fourteen centres answered this question. In 12/14 (86%) centres pathologists provide tumor stage in the histopathology report and in two centres they do not.

## **DISCUSSION**

This survey, is the first representative analysis of trends for the management of BOTs in the United Kingdom.

#### **Incidence of BOTs**

In all of the clinical departments participating in the survey, the vast majority treated no more than 25 patients with BOTs annually. Many of the centres reported treating between 10-15 cases per annum. Hence approximately 500-600 new cases of BOTs are seen in the United Kingdom annually. This finding is in line with national and international incidence data, where BOTs constitute 8%-10% of all ovarian tumors<sup>[13]</sup> and the ratio of patients with ovarian carcinoma to patients with BOTs is between 1:10 and 1:20<sup>[10,14]</sup>.

The survey showed the majority of tumors presented at stage I : 80%-97%; followed by stage II : 1%-20% and stage III : 5%-25%. This is in line with the reports in the literature which show that 85%-92% of patients with

BOTs have Stage I disease, 5.5%-7.9% have stage II and 3.5%-15% have Stage III disease<sup>[15,16]</sup>.

The data shows the incidence of serous tumors ranges between 25%-80% and of mucinous tumors from 20%-75%. Few centres reported encountering other types of BOTs representing 1%-10% of tumors seen and including endometrioid, clear cell and mixed type tumors. In most centres serous tumors were the commoner type and only few centres reported a higher incidence of mucinous tumors. This is similar to the reports in the literature where serous and mucinous tumors are the most frequent types with only few cases of endometrioid and other variants seen. In reported series, some studies show that mucinous tumors are more than serous tumors in some centres, while in other centres the pattern is reversed with serous being the most common type of BOTs encountered<sup>[11,15,17]</sup>. This would justify that protocols for diagnosis and management of BOTs should be principally based around the clinicopathological characteristics of these two most common subtypes.

At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behaviour of these tumors could be confirmed<sup>[18]</sup>. Nomura *et al*<sup>[19]</sup> studied 55 cases of borderline OInMTs without intraepithelial carcinoma to test whether these should still be considered tumors of low malignant potential. They concluded that that OInMTs, in which intraepithelial carcinoma has been ruled out, are benign tumors, not tumors of low malignant potential. The authors proposed that these tumors should be designated as high-grade mucinous adenoma, but recommended salpingo-oophorectomy rather than cystectomy for treatment, because cystectomy alone may allow local recurrence.

Chiesa *et al*<sup>[18]</sup> studied 33 FIGO stage I borderline OInMTs that were adequately sampled to exclude intraepithelial carcinoma, microinvasion, or invasive carcinoma. There were 2 cases with recurrence, secondary to incomplete excision or cystectomy, and no deaths from disease<sup>[18]</sup>. In a retrospective review of 97 patients after a median follow-up of 48 mo, 13 patients developed 14 recurrences: 7 were borderline and 7 were invasive lesions. The probability of recurrence in the form of carcinoma 5 and 10 years after the diagnosis was, respectively, 9% and 13% and the cumulative risk of recurrence in the form of invasive carcinoma at 10 years was 13%<sup>[20]</sup>.

Benito *et al*<sup>[21]</sup> showed that serous histology is significantly related to the presence of peritoneal implants, positive peritoneal cytology and bilaterality, yet the overall survival (OS) rates at 2, 5 and 10 years were 100%, 96.4% and 93.6%, respectively. However, mucinous BOTs are associated with significantly lower OS rates than serous BOTs (10 years OS: 88.5% *vs* 98.2%, *P* = 0.01). So although serous tumors present more unfavourable anatomicopathological characteristics, they are associated with better prognosis than mucinous tumors<sup>[21]</sup>.

A fact that should also be taken in consideration is that

borderline OInMTs are usually large and heterogeneous, and the standard sampling protocol for them is not evidence based and there is potential for a sampling artefact in which a focus of carcinoma is missed. Caution dictates retaining the current nomenclature to ensure the follow-up of patients affected by this disease until uncertainty regarding the extent of sampling needed to exclude the presence of carcinoma is resolved<sup>[18]</sup>. Also, limited experience with endocervical (müllerian)-type mucinous borderline tumors shows a possible relation to serous BOTs in clinicopathologic features and biologic behaviour<sup>[22]</sup>.

As mucinous BOTs do not appear to be such a “safe” disease<sup>[20]</sup>, mucinous BOT diagnosis should be retained so that physicians are aware that their aggressive potential is not negligible<sup>[21]</sup>.

### Histological assessment

The mainstay of diagnosis of BOTs is histopathology and central to this is the determination of epithelial subtype, and the recognition of invasion *vs* pseudoinvasion and microinvasion, identification of special features as micropapillary pattern and intraepithelial carcinoma and discrimination between invasive and non-invasive implants and FIGO staging<sup>[23]</sup>. It is crucial that tumors are thoroughly sampled and histologically assessed to identify all the potentially relevant histological features that may give indication to the likely behaviour of each tumor.

### Tumor sampling

The general recommendation in sampling ovarian tumors is at least 1 block per cm of the largest tumor dimension. If there is need for further sampling due to the macroscopic appearance of the tumor or due to histological features seen on examination of the original sections more blocks are taken. In the centres participating in the survey only one centre reported pathologists sample 1 block per centimetre and in another centre the pathologists sample more than 1 block per centimetre. Most centres reported that the number of blocks sampled in each case varies according to the gross appearance of the tumor, and in some centres it depends on tumor type. This is reasonable in principle as for example mucinous neoplasms may be extremely heterogeneous and more generous sampling may need to be undertaken<sup>[24]</sup>.

**Implants:** In patients with BOTs, non-invasive implants are common, whereas 6% of the women present with invasive implants<sup>[23]</sup>. Stage and subclassification of extra-ovarian disease into invasive and noninvasive implants are the most important prognostic indicators for serous BOTs<sup>[1,25,26]</sup>. The 5-year rates of evolutive invasive disease in patients with non-invasive implants and invasive implants were 2% and 31%, respectively<sup>[27]</sup>. Patients with invasive implants have a statistically significantly higher relapse rate<sup>[28]</sup>. Invasive implants behave as carcinomas and are most likely metastatic. Noninvasive implants behave in a benign fashion. Five-year survival for stage I tumors is virtually 100%. Survival for advanced stage tumors

with noninvasive implants is 95.3%, whereas survival for tumors with invasive implants is 66%<sup>[28-30]</sup>.

**Microinvasion:** In most studies, microinvasion has been found to have no adverse effect on prognosis, although foci of microinvasion in serous BOTs often coexist with other features which may be indicative of a worse prognosis, such as a micropapillary growth pattern<sup>[22,29,31-34]</sup>. However, in other studies microinvasion was associated with significantly higher recurrence and mortality rates<sup>[16,35,36]</sup> and correlated with adverse outcome, independent of stage of disease, micropapillary architecture, and implant type<sup>[23]</sup>.

**Micropapillary architecture:** Serous BOTs with micropapillary growth pattern are more frequently bilateral and exophytic and strongly associated with invasive implants and decreased OS. Molecular data suggest that such tumors may represent an intermediate stage in a typical serous BOTs-invasive low-grade serous carcinoma progression<sup>[22,23,29]</sup>. Other studies show that although a micropapillary pattern is associated with higher stage, it does not adversely affect prognosis<sup>[34,37]</sup> and that only micropapillary tumors associated with invasive implants behave aggressively<sup>[38]</sup>.

Seidman and Kurman propose that BOTs can be divided into benign and malignant subtypes providing the basis for replacing the borderline category. The benign subgroup is composed of typical serous BOTs, including those with noninvasive implants for which the term atypical proliferative serous tumor is appropriate. In contrast, tumors displaying a micropapillary growth pattern and tumors with invasive implants should be classified as carcinomas and treated accordingly<sup>[39]</sup>.

### Tumor staging

The results of the survey show that in all but one centre the pathologists consistently provide tumor stage in the report. This is extremely important as tumor stage at diagnosis is the most important prognostic marker<sup>[34,36]</sup>. The 5-year survival for women with Stage- I BOT is favourable, about 95%-97%, and the 10-year survival is only between 70% and 95%, caused by late recurrence. The 5-year survival for Stage II-III patients is 65%-87%<sup>[8,23]</sup>.

So, it is essential that BOTs are reviewed by a specialist gynaecological pathologist to ensure appropriate classification of the tumor and verification of the presence or absence of all relevant histological features. As these tumors are not common, general pathologists may not have the opportunity to see enough of these tumors in their practice to gain enough experience in assessing them thoroughly. For example employing the agreed upon criteria for the differentiation between microinvasion and frank invasion in different types of BOTs and the recognition of different patterns of invasion in mucinous tumors are important and can sometimes be difficult. Also determining the kind of peritoneal implant can be difficult in some cases.

### Surgical management

There are various modalities of surgery for the management of patients with BOTs<sup>[40]</sup>. Staging laparotomy for BOTs usually includes a hysterectomy and bilateral salpingo-oophorectomy, omentectomy together with peritoneal biopsies, washings and appendicectomy in certain instances. As BOTs frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing postoperative morbidity. Over the past several decades surgical therapy has shifted from a radical approach to more conservative treatment. In young women, clinicians perform cystectomy, unilateral salpingo-oophorectomy and biopsies of the contralateral ovary<sup>[41,42]</sup>.

High conception rates were achieved after a simple ovarian cystectomy<sup>[12,13,23,43]</sup>, but the high risk of local recurrence can be up to 75%<sup>[44]</sup>. Results of cystectomy for BOT suggest a higher risk of intraoperative cyst rupture and of recurrence when compared with unilateral or bilateral salpingo-oophorectomy<sup>[4,45]</sup>. For this reason, ovarian cystectomy or a partial oophorectomy can be performed after informing of the patient about the recurrence risk and provided that the patient is willing to undergo a careful and prolonged follow-up<sup>[42,46,47]</sup>.

The results of our survey showed when a BOT has been identified and full staging surgery has not been performed, the policies with regards to future patient management varied in different centres. Some authors believe a general recommendation for completion of full surgical staging and completion surgery cannot be suggested because of lack of a validated benefit for the patients<sup>[16,42,48]</sup>. This is due to the fact that many studies showed that following conservative surgical management for BOTs, the patient outcome is still excellent<sup>[4,49,50]</sup>. In one study recurrence rate for patients who underwent a primary pelvic clearance was 1.6% compared to fertility-sparing conservative surgery (3.3%) and no significant difference was noted in recurrence and mortality between fully staged *vs* unstaged patients<sup>[11]</sup>. In another study no patients treated conservatively had a recurrence<sup>[15]</sup>. Others have shown that the 5- and 10-year survival rates of women treated with fertility sparing surgery were 100% and thus not worse than those of radically operated patients (5- and 10-year survival 95.1% and 90.1%). Relapse rates in both groups were comparable with 10.5% and 10.0% ( $P = 0.723$ ). Hence fertility sparing surgery in women at childbearing age can be an adequate treatment option in early stage disease<sup>[28]</sup>. The overall tumor-free survival was found to be significantly decreased in cases, performing fertility-sparing surgery, but the OS rates were comparable with surgically staged patients<sup>[51]</sup>.

In contrast, other studies show that the strongest prognostic factor in patients with an advanced-stage BOT is the use of conservative surgery<sup>[37,52]</sup>. Patients who underwent conservative surgery had a higher recurrence rate (60% after conservative surgery and 8% after radical surgery)<sup>[53]</sup>.

Zapardiel *et al*<sup>[54]</sup> evaluated the role of restaging sur-

gery in the management of patients with BOTs after being incompletely surgically staged on restaging surgery. Among stage I patients 12.3% were up-staged. The up-staging rate among serous tumors was 16.2%, and 4% among mucinous tumors. There were no differences in terms of OS between patients who were upstaged and those who were not. The authors conclude that restaging procedure does not seem to have a significant impact on the management of patients diagnosed with BOTs, especially in mucinous subtype and apparent FIGO stage higher than I<sup>[54]</sup>.

However, surgical staging is important to identify invasive extraovarian implants that portend an adverse prognosis<sup>[11]</sup>. A study by Anfinan *et al*<sup>[35]</sup> included patients treated for BOTs with complete (group I) and incomplete (group II) surgical staging. Twelve patients were found to have implants as result of the staging procedure; two of them were invasive implants and both required chemotherapy. Nine (6.5%) patients experienced recurrence: five (5.6%) patients in group I *vs* four (8.2%) patients in group II. There was no difference in recurrence rates observed between the study groups. However, surgical staging is important for identifying invasive extraovarian implants that need to be treated with chemotherapy.

A prospective long-term extension study of a randomized controlled trial aimed to assess the risk-benefit ratio of an ultra-conservative fertility-sparing approach in patients with bilateral BOTs. The experimental group ( $n = 15$ ) was treated with an ultra-conservative surgical approach consisting of bilateral cystectomy, whereas the control group ( $n = 17$ ) received a less conservative surgery consisting of oophorectomy and contralateral cystectomy. All patients received a complete laparoscopic staging followed by a fertility enhancement programme. Although the time to first recurrence was significantly ( $P < 0.01$ ) shorter for the experimental group, in the regression analysis the difference did not reach the statistic significance ( $P = 0.14$ ), and the RR of recurrence (1.23, 95%CI: 0.62-3.17,  $P = 0.41$ ) was not significant. The study showed that the ultra-conservative fertility-sparing approach is more effective than the standard approach in terms of reproductive outcomes, but presents a higher oncological risk<sup>[55]</sup>.

It is clear that “biological” status of the patients inside the groups, pre-menopausal, post-menopausal or women in the reproductive age, who desire to preserve fertility should influence the decision regarding choice of conservative or radical surgical management.

### Lymphadenectomy

The one parameter that most of the centres agreed on is that lymphadenectomy is not done as part of any surgical management for BOTs. Lymph node involvement is seldom<sup>[42,46,56]</sup> and does not seem to adversely affect prognosis<sup>[22]</sup>. Hence systematic pelvic and para-aortic lymph node dissection is not recommended in BOTs. Moreover, it is not clear whether these lymph node implantations represent real metastases or, *in situ* transformed second-

ary müllerian epithelia<sup>[25,57]</sup>. Concerning the performing of lymph node resection, at least 20% of the patients with FIGO stage I have to be upgraded as belonging to FIGO stage IIIc, but the prognostic relevance is unimportant<sup>[48,58]</sup>.

Studies have shown that the intraoperative blood loss was significantly more and the hospital stay was significantly longer in patients who underwent complete lymph node dissection. However, overall and disease-free survival spans were found to be statistically similar between patients who had or did not have lymphadenectomy. Hence retroperitoneal evaluation can be spared in women with BOTs<sup>[23,59]</sup>.

### Follow up

The survey shows variability of this aspect of the practice in the UK. The majority of the centres had a follow up protocol for all patients in place, but the protocols varied in different centres. Follow up protocols varied in duration between being patient initiated, clinical visits every 3, 5, 10 and 20 years and up to for life in patients who had fertility sparing surgery. The frequency of follow up visits and modality varied as well depending on the time of surgery, type of surgery and histological type and features of the tumor and patient age. The majority of centres would send a reminder letter with a new appointment if the patient missed her appointment and some centres would in addition send a letter to the GP for persistent non attenders.

It is not surprising to find variability in follow up protocols, as there are no robust criteria to identify patients at high risk of recurrence or progression<sup>[60,61]</sup>. However, it should be the consensus that conservative surgery warrants closer follow up. Histological features of the tumor should also be considered in follow up and not just whether the patient had fertility sparing surgery. In view of the controversy about the significance of micro-invasion, intramucosal carcinoma, lymph node deposits, type of implants, it would seem appropriate that such features dictate long term follow up regardless of tumor stage.

The common modes of diagnosis of recurrences are imaging, clinical symptoms and CA 125 elevation<sup>[62]</sup>. The results of our survey show that most centres use physical examination and serum CA 125 for follow up. In some patients transvaginal ultrasound is used in addition, particularly in patients who had fertility sparing surgery. Other centres use only one or different combinations of these modalities.

CA 125 at primary diagnosis correlates with tumor stage and tends to be increased in the presence of ascites, endometriosis or peritoneal implants. Moreover, CA 125 at primary diagnosis appears to have prognostic value for recurrence<sup>[63]</sup>.

In one study serum tumor marker levels of CA 125, CA19-9, CEA, and CA15-3 were determined by radioimmunoassay in women with serous and mucinous BOTs, and respectively 48.2% and 41.8% had at least one abnormal value<sup>[64]</sup>. In another study the positive rate of



CA 125, CA 19-9, CA 15-3, and CEA in serous tumor were 57.9%, 7.9%, 7.9% and 15.8%, respectively. These figures were 31.8%, 40.9%, 27.3% and 40.9% in mucinous tumor. The positive rate of CA 125 in the serous group was statistically significantly higher than that in the mucinous group, while the positive rates for CA 19-9 and CEA in mucinous histology was significantly higher than those in serous tumors<sup>[65]</sup>. This suggests that it may be reasonable to include CA19-9 and CEA rather than or in addition to CA 125 in the follow up of patients with mucinous BOTs.

In one study the most frequent diagnostic method for invasive recurrences was blood CA 125 elevation and the majority of noninvasive recurrences were diagnosed by imaging by ultrasound<sup>[66]</sup>. It is believed that CA 125 monitoring may have a role in early detection of recurrence in patients with aggressive disease<sup>[36]</sup>. Some authors believe that CA 125 does not improve any positive or negative predictive value of the examination<sup>[56]</sup>. On the basis of the current literature, vaginal ultrasound and possibly additional Doppler ultrasound as well represent the best diagnostic tool for the detection of BOTs<sup>[62,67]</sup>.

It may be a recommendation to have both modalities of serum tumor markers and transvaginal ultrasound, as each is more sensitive to a different type of recurrence. In patients with mucinous tumor, it seems reasonable to include CEA and CA 19-9 in follow up.

### Management of relapsed disease

Patients with recurrent disease have a statistically significantly worse survival: 5- and 10-year survival rates are 90.0% and 80.0% compared with 98.9% and 94.4% for those without ( $P = 0.0208$ ), respectively<sup>[28]</sup>. Second cytoreductive surgery is recommended for patients with recurrent disease<sup>[8]</sup>. The survey showed that most centres (45.5%) treat relapsed disease by surgery only. In some centres chemotherapy is also used alone or before or after surgery especially if there is invasive disease. Fewer centres use chemotherapy in the adjuvant setting. In both situations the used regimen was carboplatin  $\pm$  taxol.

The role of chemotherapy in the management of BOTs in the adjuvant setting or in treatment of relapsed disease is not confirmed and adjuvant systemic chemotherapy is nowadays not generally indicated<sup>[9-12]</sup>. Faluyi *et al*<sup>[68]</sup> reviewed seven randomised controlled trials (RCTs) that evaluated adjuvant therapy (chemotherapy, pelvic external irradiation or intra-peritoneal radioactive isotope therapy) after radical surgery. Overall and recurrence-free survival were similar between both arms of these trials, except that one trial ( $n = 66$ ) showed a significantly lower survival ( $P = 0.03$ ) in women who received chemotherapy (thio-TEPA). The authors concluded that they found no evidence to support the use of any specific type of adjuvant therapy for BOTs<sup>[68]</sup>.

So far, there has been no phase III trials performed that explored the role of systemic therapy for patients with BOTs. Generally, platinum-based chemotherapy regimens were administered in phase II trials<sup>[58,69,70]</sup>.

Some studies showed that adjuvant treatment was of no benefit<sup>[71]</sup> and did not seem to influence progression free survival<sup>[72]</sup>. Occasional responses to chemotherapy have been reported in advanced BOTs but no study has shown improved survival<sup>[8]</sup>. Some studies show that adjuvant postoperative therapy is not indicated in Stage- I diploid tumors, but favoured in "high-risk" patients with tumor residual, microinvasion or invasive implants<sup>[8,41]</sup>.

To date the value of the currently available chemotherapeutic agents used in ovarian cancer is not established in treatment of BOTs<sup>[11]</sup>. The search for new systemic chemotherapy regimens is essential and perhaps attention should be paid to the local intraabdominal administration of drugs<sup>[73]</sup>.

### MDT discussion

The results of the survey are very reassuring as they showed that all but one centre do refer the cases for discussion in the central MDT meeting and even the one centre that does not refer all cases seems to refer any cases other than stage I A tumors that have no alarming clinical and histological features. Discussion of all cases of BOTs by the specialist MDT is essential and histology review by expert gynaecological pathologists is important. In our experience some cases on review are found to be benign. Although borderline features are present in the tumor, these may be present in less than 10% of the tumor, which should then be best regarded as a benign tumor according to the current consensus. Also some tumors diagnosed as BOT, may actually show features that justify managing them as carcinomas. Specific features as the presence of intramucosal carcinoma, microinvasion and the nature of peritoneal implants are also essential parameters to assess as previously discussed.

From the surgical point of view discussion of the surgery the patient had in relation to histological features is essential to make an informed decision whether the patient needs further surgery, adjuvant therapy and the appropriate follow up protocol for every case. So it is advocated that BOTs are discussed in the context of the MDT meeting for appropriate clinical decision making relevant to the treatment of each individual patient. This will also facilitate the collection of accurate data for cancer registries and provide feedback for those caring for the patients.

The results of our survey indicate the need for more adequate staging of patients with BOTs in some centres. Oncologic safety, as well as patients' desires and expectations, have to be balanced to reach the most appropriate treatment for BOTs<sup>[40]</sup>. More importantly a follow up program should be in place, particularly patients who had fertility sparing surgery, and all patients whose tumors show histological features that may indicate the likelihood of aggressive behaviour.

Although patients with BOTs have an excellent prognosis, the small, but significant risk of progression over time to low-grade serous carcinoma emphasizes the need for prolonged follow-up in patients with BOTs<sup>[17,23]</sup>. Re-

lapses of the S-BOTS may occur up to 50 years later so continued long-term surveillance with CA 125 evaluation and physical examination and ultrasound in patients who had fertility sparing surgery should be considered for optimal patient follow-up<sup>[73,74]</sup>. The taking on board of risk factors will enable identification of patients with high-risk factors, which is essential for offering more selective treatments to prevent recurrence<sup>[60]</sup>. None of the histopathologic criteria of the primary tumor including micropapillary subtype of the S-BOT can be used yet as a prognostic marker<sup>[73]</sup>.

RCTs evaluating the benefit of adjuvant therapy with optimally dosed chemotherapy and newer targeted drugs are necessary, particularly for advanced BOTs. The low mortality from BOTs should make recurrence-free survival, time to recurrence and morbidity important end points in such trials<sup>[68]</sup>.

Although the survey represents the practice of 46% of the networks in the United Kingdom, we believe the results are a representative of the current practice and demonstrate the variability of management in surgical intervention and follow up in different centres, which highlights the need for a national protocol for management of BOTs that offers patients across the country the same standard of care.

## RECOMMENDATIONS

There are currently no evidence based criteria for individualised patient tailored management and equally no unified international or UK national protocol for the management of BOTs. Based on the current knowledge from the literature and results of our survey of current practice in the UK, we propose the following recommendations.

### Surgical management

(1) Fertility sparing surgery is adequate for young women with early stage disease, with subsequent completion surgery on family completion; and (2) Surgical staging is important to identify the presence and type of extra-ovarian implants, which can affect prognosis.

### Histological assessment

(1) BOTs should be thoroughly sampled, at least 1 block per centimeter; (2) Histological reports should include comments on the presence of micro-invasion, micropapillary pattern, intramucosal carcinoma, presence and type of implants and tumor stage; and (3) Cases should be reported/reviewed by specialist gynaecological pathologists.

### Follow up

(1) Patients should be followed up for at least 5 years; (2) Conservative surgery, high stage disease and invasive implants warrant closer and longer term follow up; (3) Patients should be followed up by clinical examination and CA 125 levels. CA19-9 and CEA levels should also be assessed in patients with mucinous BOTs; and (4) All

women who have undergone fertility sparing should in addition have annual pelvic ultrasound for 5 years, then every 2-3 years until they have completion surgery.

## MDT discussion

All cases should be referred to and discussed in the specialist gynaecological oncology MDT meeting.

## Management of relapsed disease or patients presenting with advanced disease

Debulking surgery is the preferred management. Chemotherapy may be used in the presence of progressive invasive disease, though the activity of platinum-based chemotherapy in this group is quite low and patients should be considered for clinical trials. It is important to establish the behaviour and natural history of the disease in individuals, and a period of observation and monitoring before introducing chemotherapy will permit selection of those with more rapidly progressive disease, for whom chemotherapy is more appropriate.

## CONCLUSION

The diagnostics and therapy of BOTs requires more educational and research activities. Molecular Studies have not yet uncovered a reliable prediction of biologic behaviour, however, there is hope that future studies of the genetics and molecular biology of these tumors will lead to useful laboratory tests<sup>[8]</sup>. Studies of BOTs at a molecular and genetic level offer potential benefits, both in terms of clarifying clinical management, and illuminating differences and similarities between this entity and invasive ovarian cancer. Sophisticated modern analytical approaches when applied to a well defined cohort of BOTs, would address issues such as the prediction of tumor progression, factors determining invasion, and markers of adverse outcome.

## ACKNOWLEDGMENTS

The authors thank all clinicians who participated in the survey on behalf of their Cancer Networks which include: East Midlands, Yorkshire, South West London, North London, Mount Vernon, Northern Ireland, West London, Dorset, Kent, Sussex, Greater Midland, Merseyside and Cheshire, North Wales, Anglia, Pan Birmingham, Leicester, Northampton, Rutland and West Scotland.

## REFERENCES

- 1 Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. *Clin Obstet Gynecol* 2006; **49**: 517-525
- 2 Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. *Cancer* 2004; **100**: 1045-1052
- 3 Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, Modan B, Ben-Baruch G. Demographic and genetic characteristics of patients with borderline ovar-

- ian tumors as compared to early stage invasive ovarian cancer. *Gynecol Oncol* 2005; **97**: 780-783
- 4 **Yokoyama Y**, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, Yamada H, Yaegashi N, Okamura K, Izutsu T, Sugiyama T, Tanaka T, Kurachi H, Sato A, Tase T, Mizunuma H. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. *Br J Cancer* 2006; **94**: 1586-1591
- 5 **Manek S**, Wells M. Pathology of borderline ovarian tumours. *Clin Oncol (R Coll Radiol)* 1999; **11**: 73-77
- 6 **Cadron I**, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I. The management of borderline tumours of the ovary. *Curr Opin Oncol* 2006; **18**: 488-493
- 7 **Ji H**, Yliskoski M, Anttila M, Syrjänen K, Saarikoski S. Management of stage-I borderline ovarian tumors. *Int J Gynaecol Obstet* 1996; **54**: 37-44
- 8 **Tropé C**, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". *Eur J Gynaecol Oncol* 2009; **30**: 471-482
- 9 **Boran N**, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, Kose MF. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. *Gynecol Oncol* 2005; **97**: 845-851
- 10 **Romagnolo C**, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: results of an Italian multicenter study. *Gynecol Oncol* 2006; **101**: 255-260
- 11 **Wong HF**, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. *Int J Gynecol Cancer* 2007; **17**: 342-349
- 12 **Yinon Y**, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. *Fertil Steril* 2007; **88**: 479-484
- 13 **Tinelli R**, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. *Gynecol Oncol* 2006; **100**: 185-191
- 14 **Skárnisdóttir I**, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. *Int J Cancer* 2008; **123**: 1897-1901
- 15 **Casey AC**, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW. Epithelial ovarian tumors of borderline malignancy: long-term follow-up. *Gynecol Oncol* 1993; **50**: 316-322
- 16 **Cusidó M**, Balagueró L, Hernandez G, Falcón O, Rodríguez-Escudero FJ, Vargas JA, Vidart JA, Zamora L, Monera M, Alonso A. Results of the national survey of borderline ovarian tumors in Spain. *Gynecol Oncol* 2007; **104**: 617-622
- 17 **Carter J**, Atkinson K, Coppleson M, Elliott P, Murray J, Solomon J, Dalrymple C, Tattersall M, Duval P, Russell P. A comparative study of proliferating (borderline) and invasive epithelial ovarian tumours in young women. *Aust N Z J Obstet Gynaecol* 1989; **29**: 245-249
- 18 **Chiesa AG**, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? *Int J Gynecol Pathol* 2010; **29**: 108-112
- 19 **Nomura K**, Aizawa S, Hano H. Ovarian mucinous borderline tumors of intestinal type without intraepithelial carcinoma: are they still tumors of low malignant potential? *Pathol Int* 2004; **54**: 420-424
- 20 **Koskas M**, Uzan C, Gouy S, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Morice P. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). *Ann Surg Oncol* 2011; **18**: 40-48
- 21 **Benito V**, Lubrano A, Arencibia O, Medina N, Álvarez Eva E, Andújar M, Falcón Juan M, Falcón O. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? *Eur J Obstet Gynecol Reprod Biol* 2010; **153**: 188-192
- 22 **Acs G**. Serous and mucinous borderline (low malignant potential) tumors of the ovary. *Am J Clin Pathol* 2005; **123** Suppl: S13-S57
- 23 **Longacre TA**, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. *Am J Surg Pathol* 2005; **29**: 707-723
- 24 **Ronnett BM**, Kajdacsy-Balla A, Gilks CB, Merino MJ, Silva E, Werness BA, Young RH. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. *Hum Pathol* 2004; **35**: 949-960
- 25 **Chang SJ**, Ryu HS, Chang KH, Yoo SC, Yoon JH. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. *Acta Obstet Gynecol Scand* 2008; **87**: 476-481
- 26 **Rollins SE**, Young RH, Bell DA. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma. *Am J Surg Pathol* 2006; **30**: 457-462
- 27 **Morice P**, Camatte S, Rey A, Atallah D, Lhommé C, Pautier P, Pomel C, Coté JF, Haie-Meder C, Duvillard P, Castaigne D. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. *Ann Oncol* 2003; **14**: 592-598
- 28 **Lenhard MS**, Mitterer S, Kümper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. *Eur J Obstet Gynecol Reprod Biol* 2009; **145**: 189-194
- 29 **Seidman JD**, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. *Hum Pathol* 2000; **31**: 539-557
- 30 **de Nictolis M**, Montironi R, Tommasoni S, Carinelli S, Ojeda B, Matias-Guiu X, Prat J. Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. *Cancer* 1992; **70**: 152-160
- 31 **Bell DA**, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. *Hum Pathol* 1990; **21**: 397-403
- 32 **Kennedy AW**, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. *Cancer* 1996; **78**: 278-286
- 33 **McKenney JK**, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. *Am J Surg Pathol* 2006; **30**: 1209-1221
- 34 **Hogg R**, Scurry J, Kim SN, Friedlander M, Hacker N. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. *Gynecol Oncol* 2007; **106**: 44-51
- 35 **Anfinan N**, Sait K, Ghatage P, Nation J, Chu P. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. *Arch Gynecol Obstet* 2011; **284**: 731-735
- 36 **Buttin BM**, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. *Obstet Gynecol* 2002; **99**: 11-17
- 37 **Kane A**, Uzan C, Rey A, Gouy S, Camatte S, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Morice P. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. *Oncologist* 2009; **14**: 591-600
- 38 **Prat J**, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. *Am J Surg Pathol* 2002; **26**: 1111-1128
- 39 **Seidman JD**, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types.



- A clinicopathologic study of 65 advanced stage cases. *Am J Surg Pathol* 1996; **20**: 1331-1345
- 40 **Trillsch F**, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, du Bois A. Clinical management of borderline ovarian tumors. *Expert Rev Anticancer Ther* 2010; **10**: 1115-1124
  - 41 **Coumbos A**, Sehouli J, Chekerov R, Schaedel D, Oskay-Oezcelik G, Lichtenegger W, Kuehn W. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany. *Br J Cancer* 2009; **100**: 1731-1738
  - 42 **Cadron I**, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. *J Clin Oncol* 2007; **25**: 2928-2937
  - 43 **Marcickiewicz J**, Brännström M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. *Acta Obstet Gynecol Scand* 2006; **85**: 1496-1500
  - 44 **Suh-Burgmann E**. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. *Gynecol Oncol* 2006; **103**: 841-847
  - 45 **Poncelet C**, Fauvet R, Boccarra J, Daraï E. Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. *Ann Surg Oncol* 2006; **13**: 565-571
  - 46 **Kumpulainen S**, Kuoppala T, Leminen A, Komulainen M, Puistola U, Sankila R, Mäkinen J, Grénman S. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. *Acta Obstet Gynecol Scand* 2007; **86**: 610-614
  - 47 **Seidman JD**, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, Oliva E, Kajdacsy-Balla A, Berman DM, Copeland LJ. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. *Hum Pathol* 2004; **35**: 918-933
  - 48 **Fauvet R**, Boccarra J, Dufournet C, David-Montefiore E, Poncelet C, Daraï E. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. *Cancer* 2004; **100**: 1145-1151
  - 49 **Seidman JD**, Sherman ME, Kurman RJ. Recurrent serous borderline tumors of the ovary. *Int J Gynecol Pathol* 1998; **17**: 387-389
  - 50 **Tropé CG**, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. *Semin Surg Oncol* 2000; **19**: 69-75
  - 51 **Ayhan A**, Guvendag Guven ES, Guven S, Kucukali T. Recurrence and prognostic factors in borderline ovarian tumors. *Gynecol Oncol* 2005; **98**: 439-445
  - 52 **Laurent I**, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P. Results after conservative treatment of serous borderline tumors of the ovary with stromal microinvasion but without micropapillary pattern. *BJOG* 2009; **116**: 860-862
  - 53 **Viganò R**, Petrone M, Pella F, Rabaïotti E, De Marzi P, Mangili G. Surgery in advanced borderline tumors. *Fertil Steril* 2010; **94**: 1163-1165
  - 54 **Zapardiel I**, Rosenberg P, Peiretti M, Zanagnolo V, Sangiogni F, Aletti G, Landoni F, Boccione L, Colombo N, Maggioni A. The role of restaging borderline ovarian tumors: single institution experience and review of the literature. *Gynecol Oncol* 2010; **119**: 274-277
  - 55 **Palomba S**, Falbo A, Del Negro S, Rocca M, Russo T, Carati F, Annunziata G, Tolino A, Tagliaferri P, Zullo F. Ultraconservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. *Hum Reprod* 2010; **25**: 1966-1972
  - 56 **Hart WR**. Borderline epithelial tumors of the ovary. *Mod Pathol* 2005; **18** Suppl 2: S33-S50
  - 57 **Shiraki M**, Otis CN, Donovan JT, Powell JL. Ovarian serous borderline epithelial tumors with multiple retroperitoneal nodal involvement: metastasis or malignant transformation of epithelial glandular inclusions? *Gynecol Oncol* 1992; **46**: 255-258
  - 58 **Silva EG**, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. *Am J Surg Pathol* 2006; **30**: 1367-1371
  - 59 **Kanat-Pektas M**, Ozat M, Gungor T, Sahin I, Yalcin H, Ozdal B. Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors? *Arch Gynecol Obstet* 2011; **283**: 879-884
  - 60 **Ren J**, Peng Z, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. *Gynecol Oncol* 2008; **110**: 162-167
  - 61 **Kokawa K**, Mikami Y, Sakata H, Oki N, Tanakas T, Yamazaki M, Nakata Y, Umesaki N. Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years' experience in the Kinki District of Japan (1990-2006). *Eur J Gynaecol Oncol* 2009; **30**: 155-161
  - 62 **Reles A**, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. *J Clin Ultrasound* 1997; **25**: 217-225
  - 63 **Lenhard MS**, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friesse K, Stieber P, Burges A. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. *Clin Chem Lab Med* 2009; **47**: 537-542
  - 64 **Poncelet C**, Fauvet R, Yazbeck C, Coutant C, Daraï E. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study. *Eur J Surg Oncol* 2010; **36**: 1066-1072
  - 65 **Ayhan A**, Guven S, Guven ES, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? *Acta Obstet Gynecol Scand* 2007; **86**: 484-490
  - 66 **Uzan C**, Kane A, Rey A, Gouy S, Pautier P, Lhomme C, Duvillard P, Morice P. How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II-III serous borderline tumours of the ovary. *Ann Oncol* 2011; **22**: 631-635
  - 67 **Schem Ch**, Bauerschlag DO, Meinhold-Heerlein I, Fischer D, Friedrich M, Maass N. [Benign and borderline tumors of the ovary]. *Ther Umsch* 2007; **64**: 369-374
  - 68 **Faluyi O**, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumours. *Cochrane Database Syst Rev* 2010; **9**: CD007696
  - 69 **Gershenson DM**, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Ovarian serous borderline tumors with invasive peritoneal implants. *Cancer* 1998; **82**: 1096-1103
  - 70 **Gershenson DM**, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C. Serous borderline tumors of the ovary with noninvasive peritoneal implants. *Cancer* 1998; **83**: 2157-2163
  - 71 **Kaern J**, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. *Cancer* 1993; **71**: 1810-1820
  - 72 **Shih KK**, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, Iasonos A, Chi DS, Barakat RR, Abu-Rustum NR. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. *Gynecol Oncol* 2010; **119**: 270-273
  - 73 **Karseladze AI**. Serous borderline ovarian tumors: where are we now? *Eur J Gynaecol Oncol* 2005; **26**: 355-361
  - 74 **Rettenmaier MA**, Lopez K, Abaid LN, Brown JV, Micha JP, Goldstein BH. Borderline ovarian tumors and extended patient follow-up: an individual institution's experience. *J Surg Oncol* 2010; **101**: 18-21

S- Editor Wang JL L- Editor A E- Editor Zheng XM



Marjan Khajehei, PhD, Series Editor

## Sexuality after childbirth: Gaps and needs

Marjan Khajehei

Marjan Khajehei, Department of Sexology, School of Public Health, Curtin University, Bentley, WA 6102, Australia  
Author contributions: Khajehei M solely contributed to this paper.

Correspondence to: Marjan Khajehei, PhD, Department of Sexology, School of Public Health, Building 400, Bentley Campus, Curtin University, Bentley, WA 6102, Australia. [mar\\_far76@yahoo.com](mailto:mar_far76@yahoo.com)

Telephone: +61-401-910967

Received: March 28, 2012 Revised: July 27, 2012

Accepted: July 30, 2012

Published online: August 10, 2012

### Abstract

Childbirth is a stressful event for a majority of women and can have many consequences one of which is female sexual dysfunction. The main aim of pre- and postnatal health services is to fulfil physical and emotional needs of mothers and babies but not sexual function of women. Also, the fact that sexual satisfaction is part of general well being and mental health is generally neglected. Sexual function of women not only is affected by childbirth, but also is influenced by many other factors. One of these factors is culture and religion. Women's sexual life after childbirth has different meaning in different cultures. In many conservative societies with certain cultural and religious beliefs women are prohibited from having sex after childbirth. In these societies, women hear conflicting stories about risks and benefits of having sexual intercourse during postpartum period the majority of which may not be true. It has been reported that some women may be at greater risk of postpartum sexual dysfunction as neurobiological factors and genetics have been recently suggested to impact female sexual functioning. Considering the multidimensional nature of female sexual dysfunction, this problem cannot be resolved by a simple solution and not all postpartum women can be treated by the same protocol. Various treatment options, such as the use of medications, behavioural interventions and psychotherapy have been investigated in research studies

and there is still controversy over the issue. Regarding the fact that sexually satisfied women are more mentally healthy, routine screening during prenatal, antenatal and postnatal visits are suggested to uncover hidden difficulties with sexual functioning of women and improve their quality of life.

© 2012 Baishideng. All rights reserved.

**Key words:** Childbirth; Postpartum; Sexual dysfunction; Investigation; Intervention

**Peer reviewer:** Polat Dursun, Associate Professor, Department of Obstetrics and Gynecology, School of Medicine, Baskent University, 06990 Ankara, Turkey

Khajehei M. Sexuality after childbirth: Gaps and needs. *World J Obstet Gynecol* 2012; 1(2): 14-16 Available from: URL: <http://www.wjgnet.com/2218-6220/full/v1/i2/14.htm> DOI: <http://dx.doi.org/10.5317/wjog.v1.i2.14>

### INTRODUCTION

Female sexual dysfunction has been recognized in women of all ages. Considering the fact that childbirth is a stressful event for most women, the sexual problem is further exacerbated after childbirth when women struggle with pregnancy-induced changes and postpartum physical, physiological and psychological alterations. Issues related to postpartum sexual health including resumption and frequency of sexual intercourse after childbirth, changes in sexual desire, arousal and orgasm, level of sexual satisfaction, and experience of perineal pain and dyspareunia have been addressed, and factors that may contribute to those problems have been investigated in literature<sup>[1-3]</sup>.

### POSTPARTUM SEXUAL DYSFUNCTION: FACTS AND MYTHS

Women's sexual life after childbirth has different meaning

in different cultures. In many conservative societies sex is a taboo and even married women are not expected to speak about sexual matters. Some cultural and religious beliefs may also restrict having sex during postpartum period for many different reasons. It is reported that “post-partum sexual abstinence is a common practice by various communities world over with varying duration”<sup>[4]</sup>. Because there is no specific rule regarding the resumption of sexual intercourse after childbirth<sup>[5]</sup>, and professionals are usually reluctant to discuss issues regarding sexuality after pregnancy<sup>[6]</sup>, women turn to friends, relatives or books for information. They may hear conflicting stories about risks and benefits of having sexual intercourse after childbirth the majority of which may not have scientific basis. Therefore, the contradiction between facts and myths can significantly contribute to sexual problems of women after the baby is born<sup>[7]</sup>.

## INVESTIGATION OF FEMALES' SEXUALITY AFTER CHILDBIRTH

Pre- and postnatal health services mainly aim at fulfilling physical and emotional needs of mothers and babies but not sexual function of women, neglecting the fact that sexual satisfaction is part of general well being and mental health<sup>[8]</sup>. It has been reported that a lack of desire for sex or having difficulties with sexual functioning is one of the symptoms of depression that requires further investigations<sup>[9]</sup>. Sexually satisfied women are more mentally healthy, and this in turn promotes the mental health of family<sup>[10,11]</sup>. Therefore, routine screening during prenatal, antenatal and postnatal visits are suggested to uncover hidden difficulties with sexual functioning of women and improve their quality of life.

Some women may be at higher risk of postpartum sexual dysfunction<sup>[12]</sup>. Recent research has focused on the role of neurobiological factors and genetics in the occurrence of female sexual dysfunction. Nevertheless, no significant association has been shown between genetic factors and sexual distress in preliminary research<sup>[13]</sup>. More in-depth future scientific studies may investigate the role of genes and neurobiological elements. Their finding may help find innovative treatment options for postpartum sexual function.

## INTERVENTION OPTIONS

Female sexual dysfunction cannot be resolved by a simple solution. Not all postpartum women can be treated by the same protocol as there are many elements affecting sexual function of women. Some researchers have investigated the use of medications in the treatment of female sexual dysfunction<sup>[14]</sup>. Although there is no proven medicine to use in such cases, the potential benefits and risks of any medications for postpartum women should be carefully assessed. Any future investigations on sexual function of mothers need to be handled with special care as many postpartum women breastfeed their babies and

there is usually a possibility that medicines pass through the breast milk and harm the baby.

Behavioural interventions<sup>[15]</sup> and psychotherapy<sup>[16]</sup> are other examples of treatment approaches. The focus of these therapies is on the recognition of thoughts or behaviours that contribute to women's sexual difficulties, the improvement of communicative skills in women and the promotion of the level of sexual thoughts and fantasies. The approaches also work on mental health of women and try to enhance self-esteem and self-confidence of women suffering from sexual dysfunction. During treatment session, the therapists usually rely upon the self-reported information and put the treatments based on the patients' words. It should be taken into account that an effective treatment cannot be fulfilled unless a thorough history is taken, and a complete history cannot be obtained unless people who are in close relationship with the patients are interviewed too. This magnifies the role of partners in such cases. Sexual function of postpartum women may significantly be influenced by their partners as they are half of the equation in a coupled relationship<sup>[17,18]</sup>. Nevertheless, there is a lack of enough data in the literature on the role of partners in occurrence of postpartum sexual dysfunction as it is usually overlooked by clinicians and researchers.

## CONCLUSION

The world has moved away from earlier assumptions about lack of sexual feeling in women especially those who have given birth<sup>[19]</sup>. While research into such sensitive issue is very significant, the study of sexuality after childbirth is almost a new research topic and only a small number of researchers has evaluated the overall quality of sexual life after childbirth. In addition, there is no consistency of the results across conducted studies. Many of the studies on postnatal sexual life bear a number of limitations some of which include: application of certain criteria, use of non-validated questionnaires, and further analysis of data obtained from other non-random studies. A large-scale random study is necessary to fully evaluate sexual function of postpartum women aiming to gather detailed information on various aspects of life. Follow-up studies after several years can also be conducted in order to evaluate the effect of time on sexual function of women after childbirth.

In summary, postpartum period is an important stage in women's life that requires more research on its existing issues. The amelioration of women's sexual problems after childbirth continues to be a challenge to researchers, health care providers and clinicians. This article aims to increase awareness on sexuality after childbirth and emphasizes the need for more effective therapeutic approaches that future studies may propose. It also aims to motivate professionals in this field to search for hidden causes of female sexual dysfunction and develop innovative ideas. It is hoped that further investigations evolve a broad-minded approach to answer significant questions in sexual health research.

## ACKNOWLEDGMENTS

The article has been written whilst Marjan Khajehei has been a Curtin International Research Scholar in Australia.

## REFERENCES

- 1 **Connolly A**, Thorp J, Pahel L. Effects of pregnancy and childbirth on postpartum sexual function: a longitudinal prospective study. *Int Urogynecol J Pelvic Floor Dysfunct* 2005; **16**: 263-267
- 2 **Brubaker L**, Handa VL, Bradley CS, Connolly A, Moalli P, Brown MB, Weber A. Sexual function 6 months after first delivery. *Obstet Gynecol* 2008; **111**: 1040-1044
- 3 **Chang SR**, Chang TC, Chen KH, Lin HH. Sexual function in women 3 days and 6 weeks after childbirth: a prospective longitudinal study using the Taiwan version of the Female Sexual Function Index. *J Sex Med* 2010; **7**: 3946-3956
- 4 **Sule-Odu AO**, Fakoya TA, Oluwole FA, Ogundahunsi OA, Olowu AO, Olanrewaju DM, Akesode FA, Dada OA, Sofekun EA. Postpartum sexual abstinence and breastfeeding pattern in Sagamu, Nigeria. *Afr J Reprod Health* 2008; **12**: 96-100
- 5 **Cunningham F**, Leveno K, Bloom S, Hauth J, Rouse D, Spong C. Williams obstetrics. 23rd ed. New York: McGraw Hill, 2010: 136-167
- 6 **Dialmy A**. Sexuality in contemporary Arab society. *Social Analysis* 2005; **49**: 16-33
- 7 **Nezhad MZ**, Goodarzi AM. Sexuality, intimacy, and marital satisfaction in Iranian first-time parents. *J Sex Marital Ther* 2011; **37**: 77-88
- 8 **Stevenson RW**. Sexual medicine: why psychiatrists must talk to their patients about sex. *Can J Psychiatry* 2004; **49**: 673-677
- 9 **Lourenço M**, Azevedo LP, Gouveia JL. Depression and sexual desire: an exploratory study in psychiatric patients. *J Sex Marital Ther* 2011; **37**: 32-44
- 10 **Perlman CM**, Martin L, Hirdes JP, Curtin-Telegdi N, Pérez E, Rabinowitz T. Prevalence and predictors of sexual dysfunction in psychiatric inpatients. *Psychosomatics* 2007; **48**: 309-318
- 11 **Biddle AK**, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. *Value Health* 2009; **12**: 763-772
- 12 **Phillips NA**. Female sexual dysfunction: evaluation and treatment. *Am Fam Physician* 2000; **62**: 127-136, 141-142
- 13 **Burri A**, Rahman Q, Spector T. Genetic and environmental risk factors for sexual distress and its association with female sexual dysfunction. *Psychol Med* 2011; **41**: 2435-2445
- 14 **Brown DA**, Kyle JA, Ferrill MJ. Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction. *Ann Pharmacother* 2009; **43**: 1275-1285
- 15 **Lofrisco BM**. Female sexual pain disorders and cognitive behavioral therapy. *J Sex Res* 2011; **48**: 573-579
- 16 **Bitzer J**, Brandenburg U. Psychotherapeutic interventions for female sexual dysfunction. *Maturitas* 2009; **63**: 160-163
- 17 **DeJudicibus MA**, McCabe MP. Psychological factors and the sexuality of pregnant and postpartum women. *J Sex Res* 2002; **39**: 94-103
- 18 **Botros SM**, Abramov Y, Miller JJ, Sand PK, Gandhi S, Nickolov A, Goldberg RP. Effect of parity on sexual function: an identical twin study. *Obstet Gynecol* 2006; **107**: 765-770
- 19 **Crooks R**, Baur K. Our sexuality. 11th ed. Belmont: Thomson Wadsworth, 2011: 114-124

S- Editor Wang JL L- Editor A E- Editor Zheng XM



*ACKNOWLEDGMENTS*

## **Acknowledgments to reviewers of *World Journal of Obstetrics and Gynecology***

We acknowledge our sincere thanks to our reviewers. Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of our World Series Journals. Both the editors of the journals and authors of the manuscripts submitted to the journals are grateful to the following reviewers for reviewing the articles (either published or rejected) over the past period of time.

**Byron Asimakopoulos, PhD, Assistant Professor**, Laboratory of Physiology, School of Medicine, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece

**Chie-Pein Chen, MD, PhD**, Division of High Risk Pregnancy, Mackay Memorial Hospital, 92, Sec. 2 Zhong-Shan North Road, Taipei 104, Taiwan, China

**Emmanuel Bujold, MD, MSc, Associate Professor**, Department of Obstetrics and Gynecology, CHUQ, Centre Mère-Enfant, Université Laval, 2705 boul. Laurier, Québec, QC G1V 4G2, Canada

**Erich Cosmi, MD, PhD, Assistant Professor**, Department of Child and Woman Health, Obstetrics and Gynecology Unit, University of Padua, Via Giustiniani n 3, 35128 Padua, Italy

**Fanuel Lampiao, PhD**, Department of Basic Medical Science, Physiology Division, P/Bag 360, Blantyre 3, Malawi

**Federico Coccolini, MD**, General and Emergency Surgery Department, Ospedali Riuniti, Largo Barozzi, 1, 24126 Bergamo, Italy

**Ioannis E Messinis, MD, PhD, Professor**, Department of Obstetrics and Gynaecology, University of Thessalia, Medical School, 41110 Larissa, Greece

**Marjan Khajehei, MSc, PhD**, Sexology Department, School of Public Health, Curtin University, Bentley, WA 6102, Australia

**Polat Dursun, Associate Professor**, Department of Obstetrics and Gynecology, School of Medicine, Baskent University, 06490 Ankara, Turkey

**Shi-Yann Cheng, MD**, Department of Obstetrics and Gynecology, China Medical University Beigang Hospital, 123 Shinder Road, Beigang Town, Yunlin County 65152, Taiwan, China

**Sorina Grisar-Granovsky, MD, PhD**, Department Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem 91031, Israel





## Events Calendar 2012

January 26-30, 2012

55th All India Congress of Obstetrics and Gynaecology -2012  
Banaras Hindu University, Varanasi, India

March 27-31, 2012

2012 American College of Medical Genetics Annual Clinical Genetics Meeting  
Charlotte, NC, United States

May 3-5, 2012

Breast 2012 - IMPAKT  
Brussels, Belgium

May 9-11, 2012

III Regional Conference of the Society of Obstetrics and Gynecology  
Merida, Venezuela

May 9-12, 2012

EBCOG 2012 - 22nd European Congress of Obstetrics and Gynaecology  
Tallinn, Estonia

May 9-12, 2012

19th European Congress on Obesity ECO2012  
Lyon, France

May 10-12, 2012

ESSIC Annual Meeting  
Porto, Portugal

May 17-19, 2012

Advances in Health Care for Women Over 40  
Las Vegas, NV, United States

May 17-20, 2012

CPP 2012 - The 2nd International Meeting on Cardiac Problems in Pregnancy  
Berlin, Germany

May 24-26, 2012

7th Brazilian Congress on Menopause and Climacteric  
Sao Paulo, Brazil

June 5-8, 2012

10th RCOG International Scientific Congress (Royal College of Obstetricians and Gynaecologists)

Kuching, Sarawak, Malaysia

June 7-9, 2012

11th European Meeting Days of the French Society of Gynecology  
Paris, France

June 13-16, 2012

XXIII European Congress of Perinatal Medicine  
Paris, France

June 20-23, 2012

12th ESC Congress- Myths and misconceptions versus evidence on contraception  
Athens, Greece

July 1-4, 2012

28th Annual Meeting of the European Society of Human Reproduction and Embryology  
Istanbul, Turkey

July 5-6, 2012

British Gynaecological Cancer Society Annual Meeting  
Londres, Cuba

July 7-14, 2012

33rd World Medical and Health Games - Antalya 2012  
Antalya, Turkey

July 19-22, 2012

16th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI)  
Singapore, Singapore

August 5-8, 2012

Office Gynecology  
Snowmass, CO, United States

August 6-10, 2012

XXXIX Ob Gyn national congress  
Guatemala, Guatemala

September 5-8, 2012

21st Society of Laparoendoscopic Surgeon Annual Meeting and Endo Expo 2012  
Boston, MA, United States

September 11-14, 2012

21st Annual Congress ESGE (European Society for Gynaecological

Endoscopy)  
Paris, France

September 19-21, 2012

3rd Congress of Neonatology and 1st Congress of Reproductive Medicine  
Ciudad de Panama, Panama

September 20-22, 2012

11th Congress of the European Federation of Sexology  
Madrid, Spain

September 24, 2012

Recent Updates in the Reproductive Endocrinology and Infertility International Symposium & Workshop  
Riyadh, Saudi Arabia

October 3-6, 2012

23rd Annual Meeting the North American Menopause Society (NAMS)  
Orlando, FL, United States

October 5-7, 2012

2012 International Conference on Stillbirth, SIDS/SUID and Infant Survival  
Baltimore, Maryland

October 7-12, 2012

XX FIGO World Congress of Gynecology and Obstetrics  
Rome, Italy

October 10- 13, 2012

National Association of Nurse Practitioners in Women's Health 15th Annual Conference  
Orlando, FL, United States

October 11-14, 2012

The 15th congress on Controversies in Obstetrics, Gynecology and Infertility (COGI) congress on Building Consensus in Gynecology, Infertility and Per  
Barcelona, Spain

October 12-13, 2012

1st International Medical Congress Woman and Man. Healthy Aging  
Warsaw, Poland

October 13-16, 2012

IGCS 2012 - 14th Biennial Meeting of the International Gynecologic Cancer

Society

Vancouver, Canada

October 17-20, 2012

Central Association of Obstetricians and Gynecologists 2012 Annual Meeting  
Chicago, IL, United States

October 17-20, 2012

International Convention Of Pan-American Medical Women's Alliance.  
Guadalajara, Mexico

November 7-9, 2012

Controversies in Obstetrics, Gynaecology and Sterility International Congress  
Valencia, Spain

November 8-11, 2012

17th World Congress on Controversies in Obstetrics, Gynecology and Infertility  
Lisboa, Portugal

November 15-18, 2012

The 3rd World Congress on Building Consensus in Gynecology, Infertility and Perinatology (BCGIP): Controversies in Obstetrics, Gynecology and Infertility (COGI)  
Delhi NCR, India

November 28-30, 2012

13th Annual Congress of the Asia Pacific Association for Gynecological Endoscopy and Minimally Invasive Therapy  
Pattaya, Thailand

December 12-14, 2012


5th International Symposium on Assisted Reproduction  
Madrid, Spain

December 14-15, 2012

18th Annual Conference on Challenges in Gynecology  
New York, NY, United States

November 14-16, 2012

19th International Council on Women's Health Issue Congress  
Bangkok, Thailand



## INSTRUCTIONS TO AUTHORS

### GENERAL INFORMATION

*World Journal of Obstetrics and Gynecology* (*World J Obstet Gynecol*, *WJOG*, online ISSN 2218-6220, DOI: 10.5317) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 100 experts in obstetrics and gynecology from 33 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

#### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJOG* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJOG* is an OA journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJOG* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that ev-

ery employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

#### Aims and scope

The aim of *WJOG* is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of obstetrics and gynecology. *WJOG* covers pregnancy complications, obstetric surgical procedures, diagnostic imaging, endoscopy, reproductive endocrinology, tumors, pelvic diseases, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine, epidemiology and nursing. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to obstetrics and gynecology, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

#### Columns

The columns in the issues of *WJOG* will include: (1) Editorial: To introduce and comment on the substantial advance and its importance in the fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in the important fields, and propose directions for the future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (6) Review: To systemically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on the future work; (7) Original Articles: To originally report the innovative and valuable findings in obstetrics and gynecology; (8) Brief Articles: To briefly report the novel and innovative findings in obstetrics and gynecology; (9) Case Report: To report a rare or typical case; (10) Letters to the Editor: To discuss and make reply to the contributions published in *WJOG*, or to introduce and comment on a controversial issue of general interest; (11) Book Reviews: To introduce and comment on quality monographs of obstetrics and gynecology; and (12) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in obstetrics and gynecology.

#### Name of journal

*World Journal of Obstetrics and Gynecology*

#### ISSN

ISSN 2218-6220 (online)

#### Editor-in-Chief

**Bo Jacobsson, MD, PhD, Associate Professor**, Department Obstetrics and Gynecology, Sahlgrenska University Hospital/Ostra, SE-416 85 Gothenburg, Sweden

## Instructions to authors

### Editorial Office

*World Journal of Obstetrics and Gynecology*  
Editorial Department: Room 903, Building D,  
Ocean International Center,  
No. 62 Dongsihuan Zhonglu,  
Chaoyang District, Beijing 100025, China  
E-mail: [wjog@wjgnet.com](mailto:wjog@wjgnet.com)  
<http://www.wjgnet.com>  
Telephone: +86-10-85381891  
Fax: +86-10-8538-1893

### Indexed and Abstracted in

Digital Object Identifier.

### Published by

Baishideng Publishing Group Co., Limited

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJOG* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow

the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2218-6220/office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2218-6220/g\\_info\\_20100722175812.htm](http://www.wjgnet.com/2218-6220/g_info_20100722175812.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjog@wjgnet.com](mailto:wjog@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be



typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJOG*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no less than 256 words) and structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724060402.htm](http://www.wjgnet.com/2218-6220/g_info_20100724060402.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.



## Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[12]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462

PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorfeide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

**Electronic journal** (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

**Patent** (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

## Units

Use SI units. For example: body mass,  $m$  (B) = 78 kg; blood pressure,  $p$  (B) = 16.2/12.3 kPa; incubation time,  $t$  (incubation) = 96 h; blood glucose concentration,  $c$  (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration,  $p$  (CEA) =  $8.6 \pm 24.5$   $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724062131.htm](http://www.wjgnet.com/2218-6220/g_info_20100724062131.htm).

## Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

## Italics

Quantities:  $t$  time or temperature,  $c$  concentration,  $A$  area,  $l$  length,  $m$  mass,  $V$  volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

## Examples for paper writing

**Editorial:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724055452.htm](http://www.wjgnet.com/2218-6220/g_info_20100724055452.htm)

**Frontier:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724055537.htm](http://www.wjgnet.com/2218-6220/g_info_20100724055537.htm)

**Topic highlight:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724055651.htm](http://www.wjgnet.com/2218-6220/g_info_20100724055651.htm)

**Observation:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724055811.htm](http://www.wjgnet.com/2218-6220/g_info_20100724055811.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724055945.htm](http://www.wjgnet.com/2218-6220/g_info_20100724055945.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724060122.htm](http://www.wjgnet.com/2218-6220/g_info_20100724060122.htm)

**Review:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724060236.htm](http://www.wjgnet.com/2218-6220/g_info_20100724060236.htm)

**Original articles:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724060402.htm](http://www.wjgnet.com/2218-6220/g_info_20100724060402.htm)

**Brief articles:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724060541.htm](http://www.wjgnet.com/2218-6220/g_info_20100724060541.htm)

**Case report:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724060640.htm](http://www.wjgnet.com/2218-6220/g_info_20100724060640.htm)

**Letters to the editor:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724061237.htm](http://www.wjgnet.com/2218-6220/g_info_20100724061237.htm)

**Book reviews:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724061329.htm](http://www.wjgnet.com/2218-6220/g_info_20100724061329.htm)

[http://www.wjgnet.com/2218-6220/g\\_info\\_20100724061423.htm](http://www.wjgnet.com/2218-6220/g_info_20100724061423.htm)

**Guidelines:** [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724061423.htm](http://www.wjgnet.com/2218-6220/g_info_20100724061423.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

## Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

## Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/2219-2808/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2219-2808/g_info_20100725073726.htm).

## Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2218-6220/g\\_info\\_20100724061942.htm](http://www.wjgnet.com/2218-6220/g_info_20100724061942.htm).

## Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

## Links to documents related to the manuscript

WJOG will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

## Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

## Publication fee

WJOG is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.